Date: 2015-08-07
Type of information: Nomination
Compound:
Company: Horizon Pharma (Ireland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 7, 2015, Horizon Pharma named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert , chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon\'s Executive Committee. George Hampton joined Horizon Pharma in 2008 as a consultant and full time as a group vice president, international operations in April 2015 . Most recently, Hampton served as president and chief executive officer of a privately held technology company. He also has more than 20 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in the autoimmune (Humira®), primary care (Celebrex®), orthopedic, diabetes (Byetta®), anti-infectives and cardiovascular areas. This includes 10 product launches in roles of increasing responsibility in sales, international marketing and operations at G.D. Searle , Abbott (now AbbVie) and Amylin Pharmaceuticals . Hampton holds a bachelor\'s degree from Miami University in Oxford, Ohio .
Financial terms:
Latest news:
